Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on June 7, 2024, covering events that occurred on June 5, 2024. The filing reports on the appointment of a new director and the certified results of the Company's 2024 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Corporate Actions
- Board Appointment: Michael J. Fox was appointed to the Board of Directors and the Compensation Committee on June 5, 2024.
- Compensation Grant: Upon appointment, Mr. Fox received an option to purchase 48,800 shares of common stock. The option vests over three years (one-third on the first anniversary, with the remainder in eight equal quarterly installments).
- Indemnification: Mr. Fox entered into the Company's standard indemnification agreement, potentially exposing the Company to liabilities for legal expenses, judgments, and settlements related to his service.
Annual Meeting Results and Governance
Stockholders voted on three matters at the Annual Meeting held on June 5, 2024:
- Election of Directors: All six nominees were elected. Notable voting results included:
- Daniel R. Passeri: 13,099,740 For; 765,119 Withheld.
- Frank Morich: 7,990,004 For; 5,605,204 Withheld.
- Peter A. Kiener: 9,038,525 For; 4,822,811 Withheld.
- Ratification of Auditors: Stockholders ratified the appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024 (32,418,349 For; 1,635,231 Against).
- Executive Compensation Advisory Vote: Stockholders approved the non-binding advisory proposal on executive compensation (11,745,009 For; 1,924,707 Against).
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future outlook, specific risks, or unusual items beyond the standard indemnification obligations associated with the new director appointment.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 48,800 stock options granted to Michael J. Fox.
- Review the significant number of "Withheld" votes for directors Frank Morich and Peter A. Kiener, which exceeded 40% of votes cast for those specific nominees.
- Confirm the terms of the Director Compensation Policy referenced in the filing (Exhibit 10.17 to the 2023 10-K).
- Monitor the Company's cash position given the lack of revenue and the ongoing operational costs typical of a biopharma firm, as no financial data is provided in this specific filing.